Form 4: LIXTE Biotechnology Director Regina Brown Receives New Stock Option Grants
Insider Transaction Report
LIXTE Biotechnology Holdings, Inc. Director Regina Brown was granted 22,600 new stock options, with 12,600 vesting immediately in lieu of cash compensation and 10,000 vesting quarterly over two years.
Summary
- Regina Brown, a Director of LIXTE Biotechnology Holdings, Inc. (LIXT), reported changes in her beneficial ownership of derivative securities.
- On June 30, 2025, Ms. Brown was granted 10,000 stock options with an exercise price of $0.905 per share.
- These 10,000 options will vest in eight equal installments on the last day of each subsequent quarter, starting September 30, 2025, until fully vested, and expire on June 30, 2030.
- Additionally, on June 30, 2025, Ms. Brown was granted 12,600 stock options with an exercise price of $0.905 per share, which vested immediately.
- This grant of 12,600 options was provided in lieu of the quarterly cash compensation due to Ms. Brown under the Board Compensation Plan, and they expire on June 30, 2030.
- Following these transactions, Ms. Brown beneficially owns a total of 103,291 derivative securities (options to purchase common stock) directly.
Sentiment
Score: 6
Explanation: The document reports a routine compensation event for a director, which is generally positive as it aligns management incentives with shareholder value, but it does not contain information that would significantly alter the company's financial outlook or operations.
Positives
- The grant of stock options to a director aligns their interests with those of shareholders, as the value of the options increases with the company's stock price.
- The immediate vesting of 12,600 options in lieu of cash compensation indicates a willingness by the director to accept equity, potentially signaling confidence in the company's future.
Future Outlook
The document indicates future vesting of 10,000 stock options in eight equal quarterly installments, commencing September 30, 2025, and expiring on June 30, 2030.
Management Comments
- The grant of 12,600 stock options was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Industry Context
This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across all industries, including biotechnology, to incentivize and align management with shareholder interests.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Structure | A portion of the director's quarterly compensation was provided in the form of immediately vesting stock options (12,600 shares) instead of cash, as per the Board Compensation Plan. | 2025-06-30 | This change aligns the director's compensation more closely with the company's equity performance, potentially enhancing long-term commitment and shareholder value alignment. |
Related Party Transactions
- The grant of stock options to Regina Brown, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.
Stakeholder Impact
- Shareholders: The issuance of new stock options could lead to minor dilution if exercised, but also aligns the director's financial interests with the company's stock performance, potentially benefiting long-term shareholder value.
- Management/Directors: Regina Brown's compensation structure now includes a greater equity component, directly linking her financial incentives to the company's stock price.
Next Steps
- The 10,000 stock options granted on June 30, 2025, will begin vesting in eight equal quarterly installments starting September 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 2021-05-11 | Date exercisable and expiration date for 25,000 options to purchase common stock at $28. |
| 2021-06-30 | Date exercisable and expiration date for 10,000 options to purchase common stock at $30.3. |
| 2022-06-30 | Date exercisable and expiration date for 10,000 options to purchase common stock at $7.45. |
| 2023-06-30 | Date exercisable and expiration date for 10,000 options to purchase common stock at $5.88. |
| 2024-06-30 | Date exercisable and expiration date for 10,000 and 4,904 options to purchase common stock at $2.37. |
| 2024-09-30 | Date exercisable and expiration date for 6,269 options to purchase common stock at $1.3. |
| 2025-01-20 | Date exercisable and expiration date for 4,924 options to purchase common stock at $2.33. |
| 2025-03-31 | Date exercisable and expiration date for 9,508 options to purchase common stock at $1.21. |
| 2025-06-30 | Earliest transaction date; grant date for 10,000 and 12,600 new stock options. |
| 2025-07-08 | Signature date of the reporting person. |
| 2025-09-30 | Vesting start date for the 10,000 stock options granted on June 30, 2025. |
| 2026-05-11 | Expiration date for 25,000 options to purchase common stock at $28. |
| 2026-06-30 | Expiration date for 10,000 options to purchase common stock at $30.3. |
| 2027-06-30 | Expiration date for 10,000 options to purchase common stock at $7.45. |
| 2028-06-30 | Expiration date for 10,000 options to purchase common stock at $5.88. |
| 2029-06-30 | Expiration date for 10,000 and 4,904 options to purchase common stock at $2.37. |
| 2029-09-30 | Expiration date for 6,269 options to purchase common stock at $1.3. |
| 2030-01-20 | Expiration date for 4,924 options to purchase common stock at $2.33. |
| 2030-03-31 | Expiration date for 9,508 options to purchase common stock at $1.21. |
| 2030-06-30 | Expiration date for the 10,000 and 12,600 stock options granted on June 30, 2025. |
Keywords
LIXTE Biotechnology Holdings, LIXT, Form 4, SEC filing, stock options, director compensation, beneficial ownership, insider transaction, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.